Guselkumab, Apremilast Show Promise in Pediatric Psoriasis – Maui Derm 2026 Update

Recent discussions at Maui Derm 2026 highlighted consistent positive outcomes with existing treatments for pediatric psoriasis, offering reassurance for young patients and their families. James Song, MD, FAAD, Co-CMO and director of clinical research at Frontier Dermatology in Mill Creek, Washington, shared updates on the efficacy, safety, and tolerability of guselkumab (Tremfya, Janssen) and apremilast during a video interview. These findings represent incremental but important progress in managing a condition that can significantly impact a child’s quality of life.

Psoriasis is a chronic autoimmune disease that causes the rapid buildup of skin cells, leading to scaly, itchy patches. Whereas it can occur at any age, pediatric psoriasis – diagnosed before age 10 – presents unique challenges. The condition can manifest differently in children than in adults, and treatment approaches must be carefully considered due to potential growth and developmental impacts. According to the National Psoriasis Foundation, approximately 1.3 million children in the United States live with psoriasis.

Guselkumab and Apremilast: Dosage and Administration

Dr. Song emphasized the consistent performance of both guselkumab and apremilast in pediatric patients. A key distinction lies in the dosage requirements. Guselkumab is approved for patients weighing over 40 kilograms, while apremilast dosage is weight-based. This difference allows for more individualized treatment plans with apremilast, particularly for younger or smaller children. Apremilast now has a once-a-day extended-release formulation, offering a more convenient option for patients who previously needed to take the medication twice daily. This shift towards a simpler regimen could improve adherence and overall treatment success.

Apremilast, initially approved by the FDA in 2014 for adult psoriasis, works by inhibiting phosphodiesterase 4 (PDE4), an enzyme involved in inflammation. Clinical trials have demonstrated its efficacy in reducing the severity of psoriasis symptoms in children, but, as with all medications, potential side effects need to be carefully monitored. Guselkumab, a monoclonal antibody that selectively blocks the interleukin-23 (IL-23) pathway, has also shown promising results in pediatric psoriasis, offering a different mechanism of action to target inflammation.

Understanding Treatment Options and Individualized Care

The choice between guselkumab and apremilast, or other psoriasis treatments, depends on several factors, including the severity of the condition, the child’s age and weight, other medical conditions, and potential side effects. Topical treatments, such as corticosteroids and vitamin D analogs, are often the first line of defense for mild to moderate psoriasis. However, for more severe cases, systemic therapies like guselkumab and apremilast may be necessary.

It’s important to note that treatment decisions should always be made in consultation with a qualified dermatologist experienced in pediatric psoriasis. A thorough evaluation is crucial to determine the most appropriate treatment plan for each individual child. Parents and caregivers should openly discuss any concerns or questions they have with the dermatologist to ensure informed decision-making.

Safety and Tolerability Considerations

Dr. Song’s comments regarding the “consistent safety and tolerability” of these medications are reassuring. However, it’s crucial to understand that all medications carry potential risks. Common side effects of apremilast can include nausea, diarrhea, and headache, while guselkumab may be associated with an increased risk of infections. Dermatologists carefully weigh the potential benefits and risks of each treatment option before making a recommendation. Ongoing monitoring is also essential to detect and manage any adverse effects that may occur.

The Role of the FDA and Ongoing Research

The FDA plays a critical role in ensuring the safety and efficacy of medications used to treat pediatric psoriasis. Before a drug can be approved for use in children, it must undergo rigorous clinical trials to demonstrate its benefits and assess its risks in this specific population. The FDA also requires manufacturers to provide clear and comprehensive labeling information, including dosage guidelines and potential side effects.

Research into new and improved treatments for pediatric psoriasis is ongoing. Scientists are exploring novel therapeutic targets and developing innovative drug delivery systems to enhance efficacy and minimize side effects. Clinical trials are essential for advancing our understanding of the disease and identifying new treatment options. You can find information about ongoing clinical trials at ClinicalTrials.gov.

What’s Next for Pediatric Psoriasis Management

The field of pediatric psoriasis is continually evolving. Future directions include a greater emphasis on personalized medicine, tailoring treatment plans to the individual characteristics of each patient. Researchers are also investigating the role of genetics and environmental factors in the development of psoriasis, which could lead to new prevention strategies. Continued surveillance of treatment outcomes and long-term safety data will be essential to optimize care for children with psoriasis. The insights shared at Maui Derm 2026 represent a step forward in this ongoing effort, offering hope for improved outcomes and a better quality of life for young patients.

The FBI recently issued an alert regarding potential Iranian retaliation, though Here’s unrelated to dermatological health. LastPass has warned customers of phishing campaigns, highlighting the importance of cybersecurity vigilance. These events underscore the importance of staying informed about a range of current events, but do not directly impact the discussion of pediatric psoriasis treatment updates.